VINCRISTINE SULFATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vincristine Sulfate, and what generic alternatives are available?
Vincristine Sulfate is a drug marketed by Abic, Abraxis Pharm, Fresenius Kabi Usa, Hospira, and Teva Pharms Usa. and is included in nine NDAs.
The generic ingredient in VINCRISTINE SULFATE is vincristine sulfate. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vincristine sulfate profile page.
Summary for VINCRISTINE SULFATE
US Patents: | 0 |
Applicants: | 5 |
NDAs: | 9 |
Raw Ingredient (Bulk) Api Vendors: | 46 |
Clinical Trials: | 477 |
Patent Applications: | 4,456 |
Formulation / Manufacturing: | see details |
DailyMed Link: | VINCRISTINE SULFATE at DailyMed |
Recent Clinical Trials for VINCRISTINE SULFATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Medical College of Wisconsin | Phase 1 |
Children's Cancer Research Fund | Phase 1 |
University of Colorado, Denver | Phase 1 |